Previous 10 | Next 10 |
Pulmatrix (NASDAQ:PULM) is down -25.23% pre-market after announcing an offering of 6,745 shares of convertible preferred stock and warrants to purchase up to 5,620,834 shares of common stock. The shares of preferred stock will have a stated value of $1,000 per share and are converti...
Pulmatrix Announces $6.75 Million Registered Direct Offering PR Newswire LEXINGTON, Mass. , Dec. 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled ...
Pulmatrix (NASDAQ:PULM): Q3 GAAP EPS of -$0.15 misses by $0.08. Revenue of $1.07M (-75.5% Y/Y) misses by $1.41M. Press Release For further details see: Pulmatrix EPS misses by $0.08, misses on revenue
Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update Pulmazole contract dispute with Cipla resolved, expect to initiate Ph2b study in Q1 2023 for treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) PUR3100 (Acute Migraine Product) IND s...
Pulmatrix Announces Resolution of Contract Dispute with Cipla PR Newswire LEXINGTON, Mass. , Nov. 9, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address seriou...
Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update PUR1800 Phase 1b study is fully enrolled with data anticipated in Q1 2022 PUR1800 6-month rat and 9-month dog toxicology data may enable expansion to chronic conditions PUR3100 Phase 1/ ...
Pulmatrix appoints Director Anand Varadan PR Newswire LEXINGTON, Mass. , July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...
Pulmatrix (PULM): Q1 GAAP EPS of -$0.09 beats by $0.01.Revenue of $1.39M (-49.6% Y/Y)As of March 31, 2021, Pulmatrix had $63.4 million in cash and cash equivalents, compared to $31.7 million for the year ended December 31, 2020.Shares +0.78%.Press Release For further details see: Pulmat...
Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update PUR1800 Phase 1b data anticipated in Q4 2021 Phase 1/ Phase 2 Study for PUR3100 in acute migraine treatment on-track for study start in Q1 2022 Cash runway extends beyond anticipated PUR1...
Shares of Pulmatrix Inc. (NASDAQ:PULM) traded at a new 52-week low today of $0.92. So far today approximately 2.6 million shares have been exchanged, as compared to an average 30-day volume of 1.8 million shares. Over the past year, Pulmatrix Inc. has traded in a range of $0.92 to $3.04 ...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...